ImageneBio, Inc. (IMA) shareholders
IMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.45−0.27 (-7.26%)
Close on Nov 12, 2026Market cap $39.16MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
54.9%
6M of 11M shares
Institutional holders
35
4 new, 8 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
1 buys · 2 sales
Net bought $78.51K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Bvf Inc/Il Joint filing with Bvf Partners L P/Il (8.30%), Lampert Mark N (8.30%) and 1 more | 4,006,564 | 8.30% | 13G (passive) amendment | Dec 31, 2024 |
| Orbimed Advisors LLC Joint filing with Orbimed Capital Gp Vi LLC (9.60%) | 1,495,045 | 13.10% | 13D (active) amendment | Apr 14, 2026 |
| Trails Edge Capital Partners, LP Joint filing with Trails Edge Biotechnology Master Fund, LP (9.90%), Ortav Yehudai (9.90%) | 1,176,472 | 9.90% | 13G (passive) | Apr 14, 2026 |
| Lampert Mark N Joint filing with Bvf Partners L P/Il (9.90%), Bvf Inc/Il (9.90%) and 3 more | 1,128,647 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Blue Owl Capital Holdings LP | 959,337 | 8.51% | 13G (passive) amendment | Mar 31, 2026 |
| Otello Stampacchia Joint filing with Omega Fund VI, L.P. (8.40%), Omega Fund VI GP, L.P. (8.40%) and 2 more | 936,222 | 8.40% | 13D (active) | Apr 14, 2026 |
| Deep Track Capital, LP Joint filing with Deep Track Biotechnology Master Fund, Ltd. (7.86%), David Kroin (7.86%) | 878,516 | 7.86% | 13G (passive) | Jul 28, 2025 |
| Bvf Partners L P/Il Joint filing with Bvf Inc/Il (7.20%), Lampert Mark N (7.20%) and 1 more | 802,102 | 7.20% | 13G (passive) amendment | Sep 30, 2025 |
| Ma-Weaver Jacob Joint filing with Funicular Funds, LP (5.80%), Cable Car Capital, LP (5.80%) | 643,933 | 5.80% | 13G (passive) | Dec 29, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IMA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Bvf Inc/Il | 1,110,002 | 9.78% | $6.55M | – | 0.17% |
| Blue Owl Capital Holdings LP | 917,692 | 8.08% | $5.41M | −41,645 | 0.81% |
| Orbimed Advisors LLC | 909,269 | 8.01% | $5.36M | +530,713 | 0.10% |
| Cable Car Capital, LP | 781,599 | 6.89% | $4.61M | +26,850 | 0.10% |
| Omega Fund Management, LLC | 455,361 | 4.01% | $2.69M | – | 1.45% |
| Rtw Investments, LP | 334,445 | 2.95% | $1.97M | – | 0.02% |
| Vanguard Capital Management LLC | 320,518 | 2.82% | $1.89M | −4,637 | 0.00% |
| Trails Edge Capital Partners, LP | 282,004 | 2.48% | $1.66M | New | 0.26% |
| BML Capital Management, LLC | 200,730 | 1.77% | $1.18M | – | 0.67% |
| Monashee Investment Management LLC | 192,344 | 1.69% | $1.13M | New | 1.90% |
| BlackRock, Inc. | 135,090 | 1.19% | $797.03K | +5,876 | 0.00% |
| Renaissance Technologies LLC | 86,930 | 0.77% | $512.89K | +5,234 | 0.00% |
| Adage Capital Partners Gp, L.L.C. | 66,666 | 0.59% | $393.33K | – | 0.00% |
| Citadel Advisors LLC | 55,610 | 0.49% | $328.10K | −68,735 | 0.00% |
| Geode Capital Management, LLC | 53,512 | 0.47% | $315.76K | −6,417 | 0.00% |
| NEA Management Company, LLC | 50,005 | 0.44% | $295.03K | – | 0.02% |
| Nano Cap New Millennium Growth Fund L P | 50,000 | 0.44% | $295.00K | +20,000 | 0.23% |
| Hsbc Holdings PLC | 34,228 | 0.30% | $208.45K | −656 | 0.00% |
| Sofinnova Investments, Inc. | 31,884 | 0.28% | $188.12K | – | 0.01% |
| Vanguard Fiduciary Trust Co | 27,475 | 0.24% | $162.10K | +189 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 35 | 6M | 54.9% | 4 / 9 | 12 / 8 | 1M | 0M |
| Q1 2026 | 39 | 5M | 47.2% | 7 / 16 | 7 / 8 | 1M | 0M |
| Q4 2025 | 41 | 5M | 42.3% | 14 / 12 | 6 / 6 | 1M | 1M |
| Q3 2025 | 33 | 5M | 41.8% | 5 / 15 | 12 / 13 | 2M | 0M |
| Q2 2025 | 41 | 3M | 23.3% | 4 / 8 | 10 / 9 | 0M | 0M |
| Q1 2025 | 46 | 3M | 24.0% | 3 / 7 | 20 / 10 | 0M | 0M |
| Q4 2024 | 53 | 3M | 23.3% | 7 / 9 | 20 / 11 | 0M | 0M |
| Q3 2024 | 57 | 2M | 20.9% | 6 / 11 | 19 / 18 | 0M | 0M |
| Q2 2024 | 70 | 2M | 21.3% | 28 / 14 | 19 / 15 | 0M | 0M |
| Q1 2024 | 57 | 3M | 22.2% | 12 / 16 | 16 / 8 | 0M | 1M |
| Q4 2023 | 54 | 3M | 23.8% | 6 / 28 | 12 / 8 | 1M | 0M |
| Q3 2023 | 58 | 3M | 24.0% | 9 / 25 | 9 / 3 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
10 funds held IMA in Q2 2026, 86% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of IMA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 264,771 | 2.33% | $1.56M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 52,467 | 0.46% | $309.56K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 31,679 | 0.28% | $180.57K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 26,707 | 0.24% | $157.57K | 0.01% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 7,299 | 0.06% | $41.60K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 5,821 | 0.05% | $33.18K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 4,219 | 0.04% | $24.05K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 3,280 | 0.03% | $19.35K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 1,787 | 0.02% | $10.54K | 0.00% | Jun 30, 2026 |
| Total Stock Market Index Trust | 434 | 0.00% | $2.56K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Kristin Yarema | Chief Executive Officer, Director | 493,705 | 4.35% | Aug 17, 2026 |
| Yanina Grant-Huerta | Chief Financial Officer | 65,000 | 0.57% | Aug 17, 2026 |
| Robert B. Lally | Principal Accounting Officer | 55,582 | 0.49% | Jul 20, 2026 |
| Benjamin Porter-Brown | Chief Medical Officer | – | – | Feb 20, 2026 |
| Erin Butler | Principal Accounting Officer | 25,551 | 0.23% | Jan 2, 2026 |
| Yufang Lu | Chief Medical Officer | – | – | Aug 7, 2025 |
| Jotin Marango | Chief Financial Officer | 15,776 | 0.14% | Jul 29, 2025 |
| Joseph P. Slattery | Director | 16,000 | 0.14% | Jun 18, 2026 |
| Otello Stampacchia | Director | 455,361 | 4.01% | Jun 18, 2026 |
| David P. Bonita | Director | 753,441 | 6.64% | Jun 18, 2026 |
| Jonathan Jian Wang | Director | 1,115,005 | 9.82% | Jun 18, 2026 |
| Wei-guo Su | Director | – | – | Apr 16, 2026 |
| Advisors Llc Orbimed | Director | 287,885 | 2.54% | Apr 16, 2026 |
| Capital GP VI LLC OrbiMed | Director | 2,251,218 | 19.83% | Apr 16, 2026 |
| Genesis GP LLC OrbiMed | Director | 753,062 | 6.63% | Apr 16, 2026 |
| Stephen Hui Wang | Director | 250,721 | 2.21% | Dec 22, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Yanina Grant-Huerta Chief Financial Officer | Aug 14, 2026 | Award | +65,000 | – | – | 65,000 |
| Yanina Grant-Huerta Chief Financial Officer | Aug 14, 2026 | Award | +39,000 | – | – | 104,000 |
| Kristin Yarema Chief Executive Officer, Director | Aug 14, 2026 | Award | +254,800 | – | – | 493,705 |
| Kristin Yarema Chief Executive Officer, Director | Jul 25, 2026 | Option exercise | +38,376 | – | – | 123,776 |
| Kristin Yarema Chief Executive Officer, Director | Jul 25, 2026 | Other | +115,129 | – | – | 238,905 |
| Robert B. Lally Principal Accounting Officer | Jul 17, 2026 | Sale | −1,525 | $5.34 | $8.14K | 55,582 |
| Robert B. Lally Principal Accounting Officer | Jul 16, 2026 | Sale | −1,671 | $5.50 | $9.19K | 57,107 |
| Kristin Yarema Chief Executive Officer, Director | Mar 16, 2026 | Award | +85,400 | – | – | 85,400 |
| Erin Butler Principal Accounting Officer | Dec 30, 2025 | Award | +22,500 | – | – | 25,551 |
| Joseph P. Slattery Director | Dec 24, 2025 | Buy | +16,000 | $5.99 | $95.84K | 16,000 |
| Jotin Marango Chief Financial Officer | Jul 28, 2025 | Award | +15,776 | – | – | 15,776 |
| Jotin Marango Chief Financial Officer | Jul 28, 2025 | Tax withholding | −4,630 | $17.16 | $79.45K | 11,146 |
| Stephen Hui Wang Director | Jul 25, 2025 | Award | +50,144 | – | – | 50,144 |
| Stephen Hui Wang Director | Jul 25, 2025 | Award | +12,535 | – | – | 12,535 |
| Stephen Hui Wang Director | Jul 25, 2025 | Award | +188,042 | – | – | 188,042 |
| Jonathan Jian Wang Director | Jul 25, 2025 | Award | +971,173 | – | – | 971,173 |
| Jonathan Jian Wang Director | Jul 25, 2025 | Award | +143,832 | – | – | 143,832 |
| David P. Bonita Director | Jul 25, 2025 | Buy | +83,611 | $29.90 | $2.50M | 287,885 |
| David P. Bonita Director | Jul 25, 2025 | Option exercise | +379 | – | – | 379 |
| Otello Stampacchia Director | Jul 25, 2025 | Option exercise | +379 | – | – | 379 |
| Otello Stampacchia Director | Jul 25, 2025 | Buy | +267,556 | $29.90 | $8.00M | 454,982 |
| Advisors Llc Orbimed Director | Jul 25, 2025 | Award | +83,611 | $2.49 | $208.19K | 287,885 |
| Erin Butler Principal Accounting Officer | Jul 25, 2025 | Award | +3,051 | – | – | 3,051 |
| David P. Bonita Director | Aug 4, 2023 | Award | +153,121 | – | – | 5,582,144 |
| Advisors Llc Orbimed Director | Aug 4, 2023 | Award | +153,121 | – | – | 5,582,144 |
| David P. Bonita Director | Aug 4, 2023 | Award | +153,121 | – | – | 2,251,218 |
| Capital GP VI LLC OrbiMed Director | Aug 4, 2023 | Award | +153,121 | – | – | 2,251,218 |
| David P. Bonita Director | Jun 24, 2022 | Buy | −96,035 | $5.37 | $515.71K | 2,098,097 |
| David P. Bonita Director | Jun 24, 2022 | Buy | −65,965 | $4.37 | $288.27K | 2,002,062 |
| Capital GP VI LLC OrbiMed Director | Jun 24, 2022 | Buy | −96,035 | $5.37 | $515.71K | 2,098,097 |
| Capital GP VI LLC OrbiMed Director | Jun 24, 2022 | Buy | −65,965 | $4.37 | $288.27K | 2,002,062 |
| David P. Bonita Director | Jun 23, 2022 | Buy | −23,419 | $3.71 | $86.88K | 1,936,097 |
| Capital GP VI LLC OrbiMed Director | Jun 23, 2022 | Buy | −23,419 | $3.71 | $86.88K | 1,936,097 |
| David P. Bonita Director | Jun 22, 2022 | Buy | −66,806 | $3.55 | $237.16K | 1,912,678 |
| Capital GP VI LLC OrbiMed Director | Jun 22, 2022 | Buy | −66,806 | $3.55 | $237.16K | 1,912,678 |
| Maude Tessier Chief Business Officer | Jan 18, 2022 | Option exercise | +38,915 | $2.94 | $114.41K | 67,707 |
| Maude Tessier Chief Business Officer | Jan 18, 2022 | Option exercise | +24,606 | $4.15 | $102.11K | 92,313 |
| Maude Tessier Chief Business Officer | Jan 18, 2022 | Option exercise | +8,265 | $4.51 | $37.28K | 100,578 |
| Xiaoyan Michelle Zhang Chief Scientific Officer | Jan 11, 2022 | Option exercise | +964 | $2.15 | $2.07K | 45,439 |
| Xiaoyan Michelle Zhang Chief Scientific Officer | Jan 11, 2022 | Sale(10b5-1 plan) | −964 | $12.00 | $11.57K | 44,475 |
| Xiaoyan Michelle Zhang Chief Scientific Officer | Jan 10, 2022 | Sale(10b5-1 plan) | −36 | $12.00 | $432 | 44,475 |
| Xiaoyan Michelle Zhang Chief Scientific Officer | Jan 10, 2022 | Option exercise | +36 | $2.15 | $77 | 44,511 |
| Atlas Venture Associates Opportunity I, LLC 10% owner | Dec 14, 2021 | Sale | −5,959 | $14.00 | $83.43K | 1,241,935 |
| Jean Francois Formela Director | Dec 14, 2021 | Sale | −5,959 | $14.00 | $83.43K | 1,241,935 |
| Atlas Venture Associates Opportunity I, LLC 10% owner | Dec 13, 2021 | Sale | −8,330 | $14.64 | $121.95K | 1,247,894 |
| Jean Francois Formela Director | Dec 13, 2021 | Sale | −8,330 | $14.64 | $121.95K | 1,247,894 |
| Atlas Venture Associates Opportunity I, LLC 10% owner | Dec 10, 2021 | Sale | −11,989 | $15.03 | $180.19K | 1,256,224 |
| Jean Francois Formela Director | Dec 10, 2021 | Sale | −11,989 | $15.03 | $180.19K | 1,256,224 |
| Xiaoyan Michelle Zhang Chief Scientific Officer | Dec 10, 2021 | Option exercise | +1,000 | $2.15 | $2.15K | 45,475 |
| Xiaoyan Michelle Zhang Chief Scientific Officer | Dec 10, 2021 | Sale | −1,000 | $14.76 | $14.76K | 44,475 |
| Atlas Venture Associates Opportunity I, LLC 10% owner | Mar 30, 2021 | Buy | +125,000 | $16.00 | $2.00M | 874,634 |
| Jean Francois Formela Director | Mar 30, 2021 | Buy | +125,000 | $16.00 | $2.00M | 874,634 |
| David P. Bonita Director | Mar 30, 2021 | Buy | +375,000 | $16.00 | $6.00M | 1,845,872 |
| David P. Bonita Director | Mar 30, 2021 | Conversion | +5,429,023 | – | – | 5,429,023 |
| David P. Bonita Director | Mar 30, 2021 | Buy | +48,400 | $16.00 | $774.40K | 91,014 |
| David P. Bonita Director | Mar 30, 2021 | Conversion | +157,288 | – | – | 157,288 |
| David P. Bonita Director | Mar 30, 2021 | Conversion | +42,614 | – | – | 42,614 |
| David P. Bonita Director | Mar 30, 2021 | Conversion | +1,470,872 | – | – | 1,470,872 |
| Genesis GP LLC OrbiMed Director | Mar 30, 2021 | Conversion | +1,470,872 | – | – | 1,470,872 |
| Genesis GP LLC OrbiMed Director | Mar 30, 2021 | Conversion | +42,614 | – | – | 42,614 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
0.86%
0M shares short
Days to cover
4.0
At 0M shares a day
Change since last report
-25.1%
From 0M shares
Short volume, 20 days
40.4%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of ImageneBio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,046 shares on Oct 13, 2026 over the last 90 days.
See a number that looks wrong?